Nifty
Sensex
:
:
12987.00
44259.74
128.60 (1.00%)
431.64 (0.98%)

Pharmaceuticals & Drugs - Global

Rating :
69/99  (View)

BSE: 539268 | NSE: SYNGENE

566.95
3.60 (0.64%)
26-Nov-2020 | 3:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  564.25
  •  568.05
  •  552.65
  •  563.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  281658
  •  1596.86
  •  596.70
  •  212.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 22,534.00
  • 63.64
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 22,938.10
  • N/A
  • 9.16

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.61%
  • 0.52%
  • 6.32%
  • FII
  • DII
  • Others
  • 14.58%
  • 5.62%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.11
  • 12.69
  • 12.23

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.07
  • 9.62
  • 9.09

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.69
  • 11.31
  • 10.50

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 35.78
  • 37.11

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 5.03
  • 6.82

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 16.20
  • 22.07

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
520
465
12%
422
421
0%
607
534
14%
519
467
11%
Expenses
371
329
13%
297
300
-1%
403
374
8%
376
327
15%
EBITDA
149
136
9%
124
121
3%
204
160
28%
143
140
2%
EBIDTM
29%
29%
30%
29%
14%
14%
28%
30%
Other Income
21
24
-13%
15
20
-25%
20
21
-1%
30
18
71%
Interest
7
8
-21%
7
7
4%
9
8
16%
10
8
20%
Depreciation
69
53
31%
66
47
39%
62
44
41%
57
43
33%
PBT
94
170
-45%
66
87
-24%
153
129
19%
107
107
0%
Tax
10
42
-76%
8
15
-45%
33
29
15%
15
20
-25%
PAT
84
128
-34%
58
72
-19%
120
100
20%
92
87
6%
PATM
16%
28%
14%
17%
7%
7%
18%
19%
EPS
2.10
3.20
-34%
1.45
1.80
-19%
3.00
2.50
20%
2.29
2.17
6%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Mar 18
Net Sales
2,068
2,012
1,826
1,423
Net Sales Growth
10%
10%
28%
 
Cost Of Goods Sold
5,006
519
531
382
Gross Profit
-2,938
1,492
1,294
1,041
GP Margin
-142%
74%
71%
73%
Total Expenditure
1,447
1,408
1,290
1,033
Power & Fuel Cost
-
46
41
35
% Of Sales
-
2%
2%
2%
Employee Cost
-
580
473
380
% Of Sales
-
29%
26%
27%
Manufacturing Exp.
-
104
86
67
% Of Sales
-
5%
5%
5%
General & Admin Exp.
-
132
137
139
% Of Sales
-
7%
8%
10%
Selling & Distn. Exp.
-
11
8
6
% Of Sales
-
1%
0%
0%
Miscellaneous Exp.
-
16
14
24
% Of Sales
-
1%
1%
2%
EBITDA
621
603
536
390
EBITDA Margin
30%
30%
29%
27%
Other Income
87
96
76
136
Interest
33
35
32
23
Depreciation
254
219
164
131
PBT
420
446
415
372
Tax
66
105
84
67
Tax Rate
16%
20%
20%
18%
PAT
354
412
332
305
PAT before Minority Interest
354
412
332
305
Minority Interest
0
0
0
0
PAT Margin
17%
20%
18%
21%
PAT Growth
-9%
24%
9%
 
EPS
8.85
10.30
8.29
7.64

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Shareholder's Funds
2,176
1,968
1,720
Share Capital
400
200
200
Total Reserves
1,737
1,740
1,492
Non-Current Liabilities
325
515
613
Secured Loans
0
347
569
Unsecured Loans
0
0
17
Long Term Provisions
41
37
29
Current Liabilities
1,539
1,129
784
Trade Payables
222
224
204
Other Current Liabilities
955
678
476
Short Term Borrowings
309
191
78
Short Term Provisions
53
37
26
Total Liabilities
4,040
3,612
3,117
Net Block
1,984
1,337
1,030
Gross Block
2,967
2,121
1,661
Accumulated Depreciation
984
784
630
Non Current Assets
2,428
1,848
1,396
Capital Work in Progress
234
274
155
Non Current Investment
74
40
0
Long Term Loans & Adv.
108
122
95
Other Non Current Assets
28
76
116
Current Assets
1,613
1,764
1,720
Current Investments
738
716
158
Inventories
25
43
86
Sundry Debtors
398
339
267
Cash & Bank
282
437
967
Other Current Assets
169
225
236
Short Term Loans & Adv.
18
4
6
Net Current Assets
73
636
937
Total Assets
4,040
3,612
3,117

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Cash From Operating Activity
677
630
446
PBT
412
332
305
Adjustment
328
213
248
Changes in Working Capital
44
182
-27
Cash after chg. in Working capital
784
726
527
Interest Paid
0
0
0
Tax Paid
-107
-96
-81
Other Direct Exp. Paid
0
0
0
Extra & Other Items
0
0
0
Cash From Investing Activity
-428
-646
-349
Net Fixed Assets
-807
-579
Net Investments
-56
-598
Others
435
531
Cash from Financing Activity
-226
-72
-79
Net Cash Inflow / Outflow
23
-88
18
Opening Cash & Equivalents
165
253
234
Closing Cash & Equivalent
193
165
253

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
53
49
42
ROA
11%
10%
10%
ROE
20%
18%
18%
ROCE
20%
17%
16%
Fixed Asset Turnover
0.79
0.97
0.86
Receivable days
67
61
68
Inventory Days
6
13
22
Payable days
54
59
73
Cash Conversion Cycle
19
14
18
Total Debt/Equity
0.32
0.41
0.47
Interest Cover
16
14
17

News Update


  • Syngene International inks pact with Deerfield Discovery and Development Corporation
    20th Nov 2020, 09:04 AM

    The agreement aims to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation

    Read More
  • Syngene International, HiMedia get ICMR’s nod for COVID-19 antibody test kit ‘ELISafe 19’
    10th Sep 2020, 11:55 AM

    The ELISafe 19 antibody test kit has a sensitivity of 100% and specificity of 99%

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.